VanEck Associates
RMD icon

VanEck Associates’s ResMed RMD Stock Holding History

VanEck Associates’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Buy
50,790
+60
+0.1% +$15K 0.01% 557
2025
Q4 		$12.2M Buy
50,730
+2,783
+6% +$712K 0.01% 500
2025
Q3 		$13.1M Sell
47,947
-3,941
-8% -$1.08M 0.01% 461
2025
Q2 		$13.4M Sell
51,888
-4,959
-9% -$1.18M 0.02% 409
2025
Q1 		$12.7M Buy
56,847
+15,568
+38% +$3.63M 0.02% 411
2024
Q4 		$9.44M Buy
41,279
+1,945
+5% +$468K 0.01% 483
2024
Q3 		$9.34M Buy
39,334
+1,121
+3% +$250K 0.01% 464
2024
Q2 		$7.31M Buy
38,213
+11,629
+44% +$2.36M 0.01% 491
2024
Q1 		$5.26M Buy
26,584
+735
+3% +$135K 0.01% 562
2023
Q4 		$4.45M Sell
25,849
-5,713
-18% -$878K 0.01% 575
2023
Q3 		$4.67M Buy
31,562
+693
+2% +$125K 0.01% 521
2023
Q2 		$6.75M Buy
30,869
+3,771
+14% +$840K 0.01% 434
2023
Q1 		$5.93M Buy
27,098
+6,845
+34% +$1.49M 0.01% 450
2022
Q4 		$4.21M Buy
20,253
+3,019
+18% +$663K 0.01% 512
2022
Q3 		$3.76M Buy
17,234
+2,114
+14% +$481K 0.01% 496
2022
Q2 		$3.17M Sell
15,120
-209
-1% -$44.5K 0.01% 563
2022
Q1 		$3.72M Buy
15,329
+1,502
+11% +$363K 0.01% 571
2021
Q4 		$3.6M Sell
13,827
-481
-3% -$125K 0.01% 581
2021
Q3 		$3.77M Sell
14,308
-2,374
-14% -$649K 0.01% 521
2021
Q2 		$4.11M Buy
16,682
+11
+0.1% +$2.31K 0.01% 493
2021
Q1 		$3.23M Buy
16,671
+1,919
+13% +$385K 0.01% 511
2020
Q4 		$3.14M Buy
14,752
+4,214
+40% +$840K 0.01% 463
2020
Q3 		$1.81M Buy
10,538
+2,162
+26% +$399K 0.01% 514
2020
Q2 		$1.61M Buy
8,376
+1,671
+25% +$273K 0.01% 526
2020
Q1 		$988K Buy
6,705
+670
+11% +$107K 0.01% 574
2019
Q4 		$935K Buy
6,035
+5,330
+756% +$768K ﹤0.01% 656
2019
Q3 		$95K Buy
705
+110
+18% +$14.4K ﹤0.01% 755
2019
Q2 		$73K Buy
+595
New +$65.9K ﹤0.01% 762
2018
Q2 		– Sell
-98
Closed -$10K – 861
2018
Q1 		$10K Buy
+98
New +$9.26K ﹤0.01% 732
2017
Q2 		– Sell
-1,945
Closed -$140K – 853
2017
Q1 		$140K Buy
1,945
+136
+8% +$9.4K ﹤0.01% 720
2016
Q4 		$112K Sell
1,809
-94
-5% -$5.76K ﹤0.01% 720
2016
Q3 		$123K Buy
1,903
+516
+37% +$34.3K ﹤0.01% 700
2016
Q2 		$88K Buy
1,387
+330
+31% +$19.5K ﹤0.01% 698
2016
Q1 		$61K Buy
1,057
+165
+18% +$9.34K ﹤0.01% 715
2015
Q4 		$48K Buy
892
+243
+37% +$13.7K ﹤0.01% 680
2015
Q3 		$33K Buy
649
+99
+18% +$5.33K ﹤0.01% 730
2015
Q2 		$31K Buy
550
+109
+25% +$6.88K ﹤0.01% 738
2015
Q1 		$32K Buy
441
+209
+90% +$13.6K ﹤0.01% 723
2014
Q4 		$13K Buy
+232
New +$12.1K ﹤0.01% 756

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VanEck Associates's RMD Position: Q1 2026 in Review

VanEck Associates increased its ResMed (RMD) stake by 0.12% in Q1 2026, buying an estimated $15K and bringing the position to 50,790 shares worth $11.4M. The position accounts for 0.01% of the portfolio, ranked #557.

VanEck Associates first reported a position in RMD in Q4 2014 and has held it in 39 quarters since. The position peaked at $13.4M in Q2 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • VanEck Associates held 50,790 shares of ResMed worth $11.4M as of Q1 2026.
  • VanEck Associates bought 60 ResMed shares in Q1 2026, an estimated $15K.
  • ResMed made up 0.01% of VanEck Associates's portfolio in Q1 2026, its #557 holding.
  • VanEck Associates first reported a position in ResMed in Q4 2014 and has held it in 39 quarters since.
  • VanEck Associates's ResMed position peaked at $13.4M in Q2 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.